Here is the design of a clinical trial:

Official Title: Anticoagulation in Patients Suffering From COVID-19 Disease-The Anti-Co Trial

Included conditions:
- Anticoagulation in COVID-19 ARDS

Study Armgroups:
- {'label': 'Standard treatment', 'type': 'ACTIVE_COMPARATOR', 'description': 'In this arm the patients will be treated according to our standard anticoagulation protocol.\n\nThe patients will not be treated with Bivalirudin (the investigational drug).', 'interventionNames': ['Drug: Standard treatment']}
- {'label': 'Bivalirudin arm', 'type': 'EXPERIMENTAL', 'description': 'The patients will be anticoagulated according to the institutional HIT-protocol which uses Bivalirudin as anticoagulant.', 'interventionNames': ['Drug: Bivalirudin Injection']}

Interventions:
- {'type': 'DRUG', 'name': 'Bivalirudin Injection', 'description': 'The patients will receive iv Bivalirudin according to the institutional HIT protocol.', 'armGroupLabels': ['Bivalirudin arm'], 'otherNames': ['anticoagulation']}
- {'type': 'DRUG', 'name': 'Standard treatment', 'description': 'This group will receive standard anticoagulation with LMWH/UFH', 'armGroupLabels': ['Standard treatment']}

Primary Outcomes:
- {'measure': 'P/F ratio', 'description': 'the P/F ratio is a surrogate parameter for oxygenation in ARDS.', 'timeFrame': 'three days of intervention'}

Please estimate the sample size based on the assumption: 
A power of 80% and a dropout rate of approximately 10% are assumed.
Numbers to be randomised (sample size)
          We performed a sample size calculation and assumed the data for P/F ratio (according to literature) is normally distributed and used the mean which would be: 160 and SD is 80. We expect the treatment will improve this by 30%. In order to reach a power of 80% we would need 44 patients per group (in total 88 patients). Taking approximately 10% of dropout into account we will include 100 patients (50 in each group).